Qnexa phentermine/topiramate: Additional Phase III data

Data from a subset of 1,119 patients with pre-diabetes at baseline in the double-blind, U.S. Phase III CONQUER (OB-303) trial showed that both doses of once-daily oral Qnexa phentermine/topiramate (7.5 mg/46 mg or 15 mg/92 mg) significantly improved HbA1c, fasting glucose and fasting insulin from baseline to week 56 vs. placebo (p<0.005 for all). Additionally, a significantly greater proportion of patients treated with Qnexa achieved normal blood sugar levels vs. placebo (p=0.0016). Furthermore, a significantly greater proportion of patients treated with placebo progressed to Type II diabetes vs. Qnexa (p=0.0253). Data were presented at the European Congress on Obesity in Istanbul. Vivus previously reported that both doses of Qnexa met the co-primary endpoints of mean percentage weight loss from baseline and percentage of patients achieving >=5% weight loss vs. placebo at 56 weeks in the CONQUER trial in 2,487 overweight and obese adults (see BioCentury, Sept. 14, 2009). ...